Sarepta Therapeutics' brutal week continued Friday after European officials rejected the company's controversial gene therapy ...

The European Medicines Agency determined testing failed to prove Elevidys’ benefit and issued a negative opinion that could ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sarepta Therapeutics (SRPT – Research Report), Intercept Pharma (ICPT – Research Report) and ...

Sarepta Therapeutics (SRPT) is under Wall Street’s microscope right now.Shares dropped by 49% in a single session last week, following the release of disappointing clinical trial results ...

Detailed price information for Zimmer Biomet Holdings (ZBH-N) from The Globe and Mail including charting and trades.

Detailed price information for Alpha Teknova Inc (TKNO-Q) from The Globe and Mail including charting and trades.

Explore Sarepta Therapeutics analyst ratings and price targets (NASDAQ:SRPT) on Benzinga. Stay updated on expert opinions and forecasts for SRPT stock.

Sarepta reports a second fatal case of acute liver failure linked to Elevidys. Analyst cuts Sarepta’s rating due to uncertain safety and future revenue potential. A new wave of value and ...

Analyst’s Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions.

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Sarepta Therapeutics (SRPT – Research Report), AlloVir (ALVR – Research Report) and Bristol-Myers Squibb (BMY ...

Sarepta Therapeutics (SRPT) is under Wall Street’s microscope right now.Shares dropped by 49% in a single session last week, following the release of disappointing clinical trial results ...